Image Analysis Group (IAG), a global leader in clinical trial imaging and AI-driven biomarker solutions, has bolstered its presence in the United States with the launch of a new office located in Cambridge, Massachusetts. This strategic move places IAG’s operations and business development teams in close proximity to key players in the biotechnology and pharmaceutical sectors, facilitating stronger partnerships and offering enhanced support for clinical trials within the region.
The Cambridge office is poised to significantly contribute to IAG’s initiatives in various therapeutic fields such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic disorders. By establishing this base, IAG aims to collaborate more effectively with sponsors and contract research organizations conducting Phase I–III clinical trials and other imaging-intensive development programs. Over the next year to two years, the company plans to create employment opportunities locally, with positions anticipated in clinical imaging operations, data science, regulatory support, and business development.
IAG’s new office will play a crucial role in delivering their comprehensive imaging services, which encompass clinical trial design consultation, optimization of imaging protocols, centralized image analysis, and the delivery of data in compliance with regulatory standards. The company’s integration into the Boston life-sciences ecosystem is expected to enhance its collaboration with biotechnology firms, pharmaceutical entities, academic institutions, and clinical research centers, fostering a more integrated approach to trial support.
Globally, IAG supports clinical trials across regions including North America, Europe, and Asia-Pacific. The company partners with pharmaceutical, biotechnology, and medical technology companies, as well as contract research organizations, to manage multi-center studies. Its global operations are structured to ensure standardized imaging protocols, centralized data harmonization, and uniform imaging analysis across international trials, enhancing the consistency and reliability of trial outcomes.
Founded in 2007 and headquartered in London, Image Analysis Group operates as an imaging Clinical Research Organization (iCRO), assisting pharmaceutical, biotechnology, and medical technology companies with imaging-based clinical trial endpoints. The company’s DYNAMIKA™ platform integrates AI-driven image analysis with centralized quality control, regulatory-compliant reporting, and real-time oversight of clinical trials, serving a wide range of indications from oncology and inflammatory diseases to musculoskeletal, cardiometabolic, and rare diseases.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.